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Tuberculosis in Malta in the 21 st century 
M. J. Ebejer 
ABSTRACT: The World Health Organisation dedicated the 24th of March 1996 as World TB Day in a bid to 
promote its pUblicity campaign aimed at increasing awareness of the deteriorating situation as regards the 
treatment and control of tuberculosis. 
Today's world population is about 5,700 million and TB is by far the major cause of death from infectious 
disease in persons over five years old. WHO estimates that one third of the world's population, that is, about 
1,900 million are already infected and we know that approximately 10% of these will develop the disease. The 
real concern, however, is that current drugs may become useless. Indeed, it is estimated that more than 50 
million people are infected with drug-resistant strains. On a global scale, the main cause of drug resistance is 
poorly managed TB control programs. 
Correspondence: M. J. Ebejer, University of Malta, Medical School, G'Mangia 
This article is based on a lecture delivered to the Medical Profession at the University ofMalta, Medical School on the 
28th March 1996 on the occasion ofWorld TB Day. 
Introduction 
Dolin1 estimated the rise in incidence over the present 
decade from 143/100,000 popUlation in 1990, to 152/ 
100,000 in 1995, to 163/100,000 in the year 2000. It 
may be worth noting that the increase between the years 
1990 and 1995 is by 9/100,000 and between 1995 and 
2,000 the increase is by 11/100,000. With each passing 
decade the increase is exponential. This data comes in 
part from a detailed analysis of notifications reaching 
WHO and from population surveys or estimates where 
no notifications were forthcoming. The study took into 
account changes in the size and age structure of the 
populations. The estimated mortality of 30 million over 
this decade takes into account the 2.9 million deaths 
expected from TB in AIDS patients. Globally, the 
incidence of AIDS has yet to peak and given its negative 
influence on tuberculosis, the incidence of the latter is 
also expected to continue to rise2• 
Against this background, it is timely to review the 
subject of tuberculosis in Malta. Today's control of TB 
in Malta is excellent thanks to the achievements of our 
predecessors. This is a good opportunity to highlight the 
historical landmarks, to assess current risks and to 
consider what might happen if we lose our current hold 
on the disease. 
Recent History of TB control in Malta3 
The first official notifications of TB began in 1920. In 
1946, the health department established a tuberculosis 
service and its public health aspect was to be run by Or 
Zammit Tabona. In the same year streptomycin became 
available but this was used initially to treat miliary and 
meningeal tuberculosis, until PAS became available a 
few years later and the two were increasingly used in 
combination to treat all forms of TB. As the rest of the 
western world em barked on a mass vaccination 
campaign with BCG, so did Malta. Supported by the 
International Commission for the Control of 
Tuberculosis, a Norwegian team came to Malta in 1949 
to help set up mass tuberculin testing and a BCG 
campaign. In the first wave, between March and June of 
1950, over 54 thousand people were tested and over 38 
thousand vaccinated. The high tuberculin positive rate 
of 28.7% at that time reflects the percentage of the 
population already infected. The major turning point as 
elsewhere in the world came in 1952 with the 
availability of the highly effective drug isoniazid. 
During that year there were 64 artificial pneumothoraces 
induced, 15 thoracoplasties, 18 internal apical 
pneumolyses, 2 cistostomies and 2 phrenic nerve 
crushes. From then on, surgery for pulmonary TB 
declined rapidly . 
The effects of TB control and treatment on the 
incidence of pulmonary TB in Malta are shown in Fig. 1. 
The trough during the war years possibly reflects a 
degree of under-reporting. The peak just after the war 
may have been due, partly, to a "catching-up" in 
reporting but probably also to a real rise in incidence as 
a result of a deterioration in social conditions during the 
war. It is worth noting that before the war, isolation of 
infectious cases and improving social conditions had 
already begun to reduce the incidence of pulmonary 
tuberculosis. The absolute figures of pulmonary 
tuberculosis, based on notifications between 1950 and 
1995 show a steady decline to present day very low 
levels, with even the year to year variation diminishing 
(Fig. 2). The absolute number of deaths plotted on the 
same time scale (Fig. 3) show the dramatic effect of 
multiple drug treatment. Mortality was halved within 
two years . The steady fall in death rate thereafter 
mirrors the reduction in incidence and the effectiveness 
of treatment. 
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Fig. 1 - Crude incidence of Pulmonary Tuberculosis 
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Fig. 2 - Pulmonary Tuberculosis in Malta 










o	 · - ~~ 

~ ~ ; ; 

Year 
Fig. 3 - Deaths from Pulmonary Tuberculosis 
in Malta, 1950 - 1995 
What is the risk of getting TB in Malta today? 
Several factors may interact around an individual to 
place that person at a greater or lesser risk of contracting 
tuberculosis (Fig. 4). The first obvious one is the 
prevalence of the disease in the general population. A 
high prevalence will increase the chances of exposure to 
one or several cases, and repeatedly so during a lifetime. 
The prevalence of tuberculin positivity in the general 
population is a direct measure of exposure and 
infectivity4.5. A heavy exposure such as when in close 
contact with a family member or a colleague at work 
will greatly increase the risk of infection6. Once 
infected, there are other factors which may determine 
whether or not this will progress to produce the disease 
of tuberculosis. One factor is the infective dose. A very 
large number of inhaled organisms over a short period 
of time is more likely to result in disease than a small 
number? The process may be accelerated in the case of 
very low or absent immunity or be greatly delayed or 
even halted in those with good immunity. Previous 
minor infections tend to favour the development and 
maintenance of immunity, but increasing age brings 
with it waning immunity and risk of breakdown of 
previously stable lesions as well as an increased risk of 
disease with each infecting dose8• Inadequate treatment 
saves lives but fails to cure. The result is that more 
persons with infection, over a longer time scale, are 
available in the community to spread the disease. There 
is no evidence that the virulence of the tubercle bacillus 
has changed significantly but it is known that resistance 
to treatment is the result of genetic alteration of the 
bacillus9. The single most important cause of reduced 
population immunity has been the spread of HIYIO. This 
has had a dramatic effect on those populations where TB 
was common in the first place. It is believed that an 
improvement in the socio-economic status of the general 
popUlation has helped to reduce the spread of the 
disease. But proof is difficult to come by. In present 
day circumstances, the risk of anyone getting TB in 
Malta must be very small. Since the number of cases of 
TB in Malta are so few, and the risk of getting TB is so 
low, why then are we concerned with what the World 
Health Organization is calling an epidemic? Is it really 
an epidemic? 1 1 
Is the global increase truly an epidemic? 
This issue has been debated in the medical literature 
and there is general agreement that there is cause for 
concern 12-15. In a schematic model of the evolution of 
an epidemic (Fig. 5), the time scale on the X axis will 
vary greatly according to the disease in question. For 
example, in the case of cholera this whole sequence can 
take place in months. In the case of TB it is probably 
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Fig. 5 - Schematic model of the evolution of an epidemic 
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best to interpret this axis in tenns of decades at least. It 
is important to realise that decades will apply as much to 
the development of a TB epidemic as to its control. As 
a general rule, epidemics escalate more and more 
rapidly until a peak is reached. After a short plateau the 
number of cases falls, initially slowly, until a low 
baseline level of prevalence is again reached. 
Epidemics are generally triggered by factors which 
bring large numbers of non-immune people in close 
contact with a source of infection. In the absence of 
treatment, it is the gradual development of immunity in 
the general population which limits the epidemic l6. 
With tuberculosis, the western world is at the lower end 
of the upslope. Many underdeveloped countries with a 
high incidence of TB were, ten to twenty years ago, on 
the down slope but the recent crisis has plateaued the 
fall or, in some cases, even reversed it l7 . Since the 
growth in incidence is exponential it would be foolish 
indeed to wait for even larger numbers to become 
infected before action is taken, particularly when we are 
seeing a loss of therapeutic efficacy of our drugs 
because of increasing resistance, falling health budgets, 
collapsing TB control programmes and, generally, loss 
of medical expertise in the condition 18. The WHO 
believes that globally, the battle against tuberculosis is 
being lost. 
Malta is fortunate not to have any of these problems at 
present. However, it must be remembered that the 
tubercle bacillus needs neither passport nor visa to enter 
Malta l9 And our nationals are not endowed with some 
special immunity against TB; so that they who spend 
time abroad in countries where TB is more prevalent are 
at increased risk. 
Will it return? 
This must remain an open question. Suffice it to say 
that many western nations with excellent records of TB 
control have seen a resurgence of the disease20. Two 
sUb-populations have been particularly affected: the HIV 
positive / drug abusing population , and immigrants; 
whether as refugees or as temporary or pern1anent 
labour force21-23 . Immigrants are more likely to have TB 
not only because many come from countries with higher 
prevalence rates, but also because their socio-economic 
status in the adopted country often puts them at greater 
risk of breakdown of their old infection, and their slow 
integration often delays their seeking medical help24. In 
Malta we are seeing greater numbers of refugees as well 
as children adopted from abroad. We do not feel these 
are a threat as they are well screened and, when 
necessary, treated. However, the same cannot be said 
for imported labour, which is also on the increase. 
There are loop-holes in the mechanisms for obtaining a 
work permit and for medical checks. Within this group, 
there have been cases of TB, one of which was isoniazid 
resistant. The matter has been taken up with the 
relevant authorities and we hope procedures will be 
reviewed and modified. It would take only one person 
with sputum positive pulmonary tuberculosis, infected 
with multi-drug resistant organisms to go undetected for 
a few months, to very seriously undermine our present 
safety. If TB did return, it is likely to return in small 
numbers initially and provided these are identified and 
the infecting bacilli are sensitive to first line drugs, the 
outbreak will be contained. If multi-drug resistant 
organisms become established, particularly in sub­
populations who may be difficult to seek out and to 
monitor, then an outbreak will certainly be more 
difficult to contain. Less patients will be cured; there 
will be a need for isolation beds; health-care personnel 
will be at greater risk25 ,26, 
What impact will HIV have? 
In 1984, the first reports emerged which showed that 
TB was more common in HIV positive individuals and 
this was mainly because of reactivation of old infection 
as their immunity waned27 , These patients were treated 
with the usual unsupervised antituberculous 
chemotherapy regimen, This appeared to be as effective 
as in HIV negative cases28 . However, these patients 
defaulted more frequently, both from follow-up and 
from taking their full course of prescribed treatment. 
They also lacked the immunity required to contain the 
disease and many returned to being sputum positive with 
high bacillary counts generally for longer periods 
because their organisms became resistant29, 
By 1989, reports of multi-drug resistant cases were 
published30, These patients had a median survival of 
only 2,1 months compared to 14.6 months if their 
organisms were fully susceptible to standard drugs, In 
1992, reports emerged that nosocomial transmission of 
multidrug resistant strains was occurring31 , This hospital 
cross infection was taking place from the patient with 
resistant bacilli to other patients receiving treatment for 
susceptible organisms, to previously uninfected persons 
and to health care personnel. Health care personnel 
have a 30% risk of becoming infected with multidrug 
resistant bacilli compared to a 2% risk if the organisms 
were sensitive32-34, This is because patients with sputum 
positive susceptible TB, when treated, are rendered non­
infectious very quickly 7, Their carers are therefore little 
exposed, Conversely, resistant bacilli remain in the 
sputum in large numbers, so that the duration and 
quantity of exposure is that much greater. 
Freiden35 illustrated the impact of AIDS and multi­
drug resistant tuberculosis on mortality, Whereas young 
non-AIDS patients can expect almost 100% cure and 
survival, those with AIDS have a much higher mortality 
and those with AIDS and multi-drug resistance are 
nearly all dead within a year. There are now HIV 
positive individuals, infected with tubercle bacilli which 
are resistant to as many as seven different drugs36, The 
prevalence of TB in HIV positive persons is highly 
variable. For example it is in the region of 6% in the 
UK and 20-70% in some African countries37. The 
clinical and radiological presentations are often atypical 
and in western countries, the organism is frequently 
another species of Mycobacterium, commonly M. 
avium-intacellulare. The problems of TB in HIV 
positive patients are summarised in Table P8-40. 
Although in Malta they are numerically small, persons 
who are HIV positive present a difficult problem. There 
is much secrecy surrounding their managment. Their 
assessment for TB, tuberculin status, prophylaxis and 
treatment is. not in the hands of those doctors with 
experience in diagnosing and treating TB. The isolation 
requirements of HIV patients with tuberculosis and their 
treatment needs to be much more stringent than those 
for ordinary patients. 
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Table 1 - Tuberculosis in HIV positive persons 
• Prevalence is very variable and presentation often atypical 
• Organism is often an opportunistic Mycobacterium 
• Tuberculin test and sputum smear are frequently negative 
• Worse prognosis both for TB and HIV 
Need for life-long prophylaxis 
• Drug resistance and cross infection more common 
Should we modify our TB control policy? 
Events have shown that the policy adopted by our 
predecessors was highly effective. This policy has been 
modified gradually over the years and today it does not 
differ significantly from the recommendations of the 
British Thoracic Society4l and the American Thoracic 
Society42. The very low incidence of TB in our Islands 
is owing to the meticulous and persistent efforts of those 
who, firstly decided to establish a control programme 
and. secondly to those who worked solidly for many 
years to identify and treat infected individuals and 
screen their contacts. In this respect we must pay a 
special tribute to Dr A. Lanfranco who for over 40 years 
was largely responsible for the management of 
tuberculosis. He strove towards and achieved the 
excellent results we enjoy today. The value of 
diagnosing and supervising the treatment and contact 
screening of all patients with tuberculosis by specialists 
is well established. General physicians and surgeons 
should not, in a modem health care system, manage 
such patients on their own43 . Particularly serious is the 
failure to notify cases or to institute adequate therapy. 
The solid foundations of a good control policy should 
not be undermined by unnecessary modernisation or by 
short-sighted cut-backs. On the contrary, any loop-holes 
which have evolved because of changes in our society 
should be tackled promptly. 
But, if TB did return what can we expect? 
Rapid diagnostic methods rely firstly upon efficient 
sample collection, either by sputum induction44 or via 
the fiberoptic bronchoscope4s , followed by the 
examination of samples inicroscopically. This last 
remains essential and it is very quick and useful. Rapid 
culture techniques are also available. They confirnl the 
diagnosis sooner and they are particularly useful to 
allow drug sensitivities to be given earlier46,47. For our 
small numbers and, so far, absence of drug resistance, 
these methods are not cost effective. DNA analysis 
using the polymerase chain reaction, once set up, is 
cheap to run . It can, in a few hours, confirm the 
presence or absence of mycobacterial DNA. It can also 
identify the very genetic status of the infecting bacillus 
and help substantially to identify the source of the 
infection48-SO . But, in the context of public health 
medicine and the control of an epidemic, these 
techniques are. in a sense, closing the gate once the 
horse has bolted. Useful as they are for individual 
diagnosis or small scale epidemiological studies, it 
remains for effective public health policies and 
treatment strategies to control the disease in the general 
population. 
The impact of drug resistance 
In HIV -negative cases with susceptible bacilli, 
treatment with the standard three drug regimen is 
. expected to result in only 0.5% treatment failure and a 
9.2% risk of relapse. Resistance to one drug results in 
11.4% treatment failure and a 24.4% risk of relapse. In 
years past, with non-HIV positive cases these effects of 
drug resistance though measurable. were manageable . 
The relapsers were re-treated with a new regimen. using 
some of the second line drugsSI . With poor supervision, 
inadequate drug supplies , false economies where poor 
quality drugs or only two in combination were used, the 
frequency of drug resistance rose. With HIV, where 
bacillary populations in individual patients are high, 
noncompliance with treatment and loss to follow-up 
more frequent , resistance to several drugs 
simultaneously in the same patient has occurred more 
easily. Although patient noncompliance remains the 
main cause, the frequency of physician noncompliance 
must not be underestimated. The factors which interact 
to produce noncompliance have been extensively 
reviewed52-S6. The causes of drug resistance are 
summarised in Table 2. 
Table 2 - Causes of Drug Resistance 
• Poor quality drugs 
• Inadequate drug regimen 
• Intemlittent or inadequate drug supplies 
• Doctor / patient error 
• Physician noncompliance with recommended regimen 
• Patient noncompliance with treatment 
Treatment strategy 
Directly observed treatment protocols have long been 
available. More recently, their advantages have been 
better appreciated, particularly in the context of patient 
groups like drug abusers, immigrants and the homeless, 
where failure of follow-up is more IikelyS7.58. Directly 
observed treatment in short course has been shown to be 
cheaper and more efficacious. As shown in a study in 
TexasS9• acquired resistance fell seven fold, the rate of 
relapse fell to a quarter as did relapsers with multi-drug 
resistant organisms. Although this study can be 
criticised because the cohorts were studied in sequence 
and not simultaneously, it nevertheless, demonstrates the 
marked benefits of supervised treatment. The later 
cohort should, if anything, have been worse off, since 
homelessness, drug abuse, and prevalence of HIV and 
TB in the general popUlation had all increased. 
Although some new drug formulations and derivatives 
are available60.6l , no major new entity is envisaged or 
likely to be so in the near future. There is some hope in 
the use of drugs already available for other diseases, for 
example: amikacin, tetracycline, ofloxacin and 
c1arithromycin. These drugs exhibit some efficacy 
against mycobacteria62-67 . Their role is still being 
evaluated. Immunotherapy with killed Mycobacterium 
vaccae is effective68 . Patients with tuberculosis who are 
vaccinated are more likely to heal and do so more 
quickly irrespective of their other treatment. This mode 
r 
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of therapy is not in general use but it may have a role in 
those who are unable to receive first line drugs, for 
whatever reason. It is unlikely to be of benefit to 
immunosuppressed persons. These individuals, 
however, might benefit from the outcome of new 
research into auxotrophic strains of BCG69. 
(Auxotrophic strains are produced by the molecular 
biological technique of "insertional mutagenesis" to 
produce a strain which cannot survive without specific 
amino acids; in this case, methionine, leucine, isoleucine 
and valine.) Although these strains can revert gradually 
to the normal organism, the rate is extremely low. Thus 
the strain eventually dies in the host, so that should 
immunodeficiency progress, dissemination cannot take 
place. Yet, there appears to remain in the host enough 
immunity to allow the development of useful protection 
against infection. 
Will surgery make a come-back? 
Given that there are cases now which cannot be cured 
by drugs, this is a very pertinent question. Extensive 
disease which is caused either by multi-drug resistant 
organisms or extensive disease not responding to 
treatment has been effectively cured by surgical 
resection. Iseman70 gives the following results of 
surgery, with or without chemotherapy: 83% long term 
cure if resectable; 11 % long term morbidity' (oxygen 
dependence); 2% mortality. 
Conclusion 
It would be wrong to paint too gloomy a picture. TB 
in the majority remains eminently curable. In a number 
of cases it presents a challenge to the clinician but it is 
still manageable. Only in very few instances is it 
un treatable. Our anxiety is that this very small group is 
increasing and we have no therapeutic armamentarium 
with which to control it. The need for strict public 
health surveillance and for adherence to proven 
treatment regimens is therefore of paramount 
importance. One cannot emphasize more strongly, the 
extreme importance of ensuring not only that the correct 
treatment is given, but also that cure with sterilization is 
actually achieved in all patients as rapidly as possible. 
Whilst there is certainly' no cause for alarm in Malta, 
politicians who are in a position to act, and those 
medical authorities who formulate national health 
policies, should note the pitfalls and correct them before 
we, too, begin to climb the steep slope of an epidemic in 
our country. 
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Hospices and hospitals 
st. Joseph hospital, Zebbug 
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The idea of a hospice for the old and sick people in 
Zebbug was first mooted about two hundred years ago A 
on the instigation of Dun Giuseppe Pullicino and the " phannacist Vincenzo Farrugia. It was inaugurated on 19 
March 1788 and developed by generous bequests from 
several Zebbug personalities. It has catered mainly for 
the elderly and orphans but in the uprising against the 
French served as a hospital for the injured. It is now a 
home for elderly females run by Franciscan Sisters of 
the Sacred Heart. The building faces a charming tree 
lined square. 
The information supplied by the Hon Michael Bonnici 
MP is gratefully acknowledged. 
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